ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO2416

Low Magnesium Predicts Cardiovascular Outcomes in Pre-Dialysis CKD Patients: Results from the KNOW-CKD Study

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Kang, Minjung, Seoul National University College of Medicine, Seoul, Korea (the Republic of)
  • Kang, Eunjeong, Ewha Womans University, Seoul, Korea (the Republic of)
  • Han, Seung Seok, Seoul National University College of Medicine, Seoul, Korea (the Republic of)
  • Ahn, Curie, Seoul National University College of Medicine, Seoul, Korea (the Republic of)
  • Oh, Kook-Hwan, Seoul National University College of Medicine, Seoul, Korea (the Republic of)
Background

There are few large-scale studies of the association between magnesium (Mg) and cardiovascular (CV) outcomes in pre-dialysis chronic kidney disease (CKD) patients. Therefore, we analyzed the effects of Mg on CV outcomes in a large-scale cohort of pre-dialysis CKD patients.

Methods

We investigated the association between serum Mg and CV outcomes in a prospective, multi-center cohort of pre-dialysis CKD patients (n=1,646). Patients were divided into four groups according to serum Mg concentration. The primary endpoint was composite outcome, defined as either a CV event and/or all-cause death. Secondary outcomes were coronary artery calcification (CAC) progression and arterial stiffness progression as assessed by mean brachial-ankle pulse wave velocity (baPWV).

Results

During a median follow-up of 6.0 years, 196 (11.9%) patients had the composite outcome of a CV event and/or all-cause death. In a multivariable cause-specific model, patients in the lowest Mg group (serum Mg ≤2.0 mg/dL) had an elevated risk of a composite outcome (hazard ratio (HR) 1.71 [1.02−2.84]; P=0.038; serum Mg =2.2 mg/dL as the reference group). Subgroup analyses showed that low Mg was particularly associated with risk of a composite outcome in patients with early CKD and those who were male. Patients in the lowest Mg group also had increased risks of progression to CAC and arterial stiffness relative to the reference group (Mg =2.2 mg/dL).

Conclusion

Low Mg level is a predictor of cardiovascular outcomes in pre-dialysis CKD patients.